سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Hayati, Hadi, Kebriaeezadeh, Abbas, Ehsani, Mohammad ali, Nikfar, Shekoufeh, Akbari Sari, Ali, Troski, Mehdi, Molla Tigabu, Bereket. (1395). Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article. , 4(12), 4033-4041. doi: 10.22038/ijp.2016.7791
Hadi Hayati; Abbas Kebriaeezadeh; Mohammad ali Ehsani; Shekoufeh Nikfar; Ali Akbari Sari; Mehdi Troski; Bereket Molla Tigabu. "Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article". , 4, 12, 1395, 4033-4041. doi: 10.22038/ijp.2016.7791
Hayati, Hadi, Kebriaeezadeh, Abbas, Ehsani, Mohammad ali, Nikfar, Shekoufeh, Akbari Sari, Ali, Troski, Mehdi, Molla Tigabu, Bereket. (1395). 'Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article', , 4(12), pp. 4033-4041. doi: 10.22038/ijp.2016.7791
Hayati, Hadi, Kebriaeezadeh, Abbas, Ehsani, Mohammad ali, Nikfar, Shekoufeh, Akbari Sari, Ali, Troski, Mehdi, Molla Tigabu, Bereket. Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article. , 1395; 4(12): 4033-4041. doi: 10.22038/ijp.2016.7791

Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article

Journal of Pediatric Perspectives
مقاله 7، دوره 4، شماره 12 - شماره پیاپی 36، اسفند 2016، صفحه 4033-4041    اصل مقاله (569.91 K)
شناسه دیجیتال (DOI): 10.22038/ijp.2016.7791
نویسندگان
Hadi Hayati1؛ Abbas Kebriaeezadeh1؛ Mohammad ali Ehsani* 2؛ Shekoufeh Nikfar1؛ Ali Akbari Sari3؛ Mehdi Troski1؛ Bereket Molla Tigabu4
1Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2Department of Pediatric Hematology and Oncology, Bahrami Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, IR Iran
4International Campus, Department of Pharmacoeconomics and Pharmaceutical Management Haramaya University School of Pharmacy.
چکیده
Background                                              
Pediatric acute lymphoblastic leukemia (ALL) is the most common, yet curable childhood malignancy within the pediatric cancers; but in most developed and developing countries cost of cancer treatment in children with ALL is high. So, we specified the range of expenses for the treatment of pediatric cancer and compared the results in developed and developing countries.
Materials and Methods
To evaluate treatment costs in childhood ALL, a review was taken place through published papers during the years 2000 to 2015. We searched multiple well known databases such as Medline, Scopus, ISI Web of Science and Google Scholar on January 2015 with "cost effectiveness", "cost utility", "cost minimization", "cost analysis", "economic evaluation", "childhood", "acute lymphoblastic leukemia", and "ALL" as our keywords.
Results
Regarding the reviewed evidence the essential result was that the total costs for treatment of pediatrics ALL in developing countries such as Asian countries were considerably lower than the costs reported from high income countries in Europe and North America. So different protocols were performed to treat ALL and this matter was significant due to the different durations of hospitalization.
Conclusion
According to the results, the total costs for treatment of pediatrics ALL in developing countries were considerably lower than the costs reported from high income countries.
کلیدواژه‌ها
Acute Lymphocytic Leukemia؛ Children؛ Costs؛ Developed Countries؛ Developing countries
آمار
تعداد مشاهده مقاله: 2,742
تعداد دریافت فایل اصل مقاله: 2,770